Tenaya Therapeutics, a clinical-stage biotechnology company, reported a net loss of $26.864 million for Q1 2025, an improvement from the $32.228 million loss in Q1 2024. The company's operating expenses decreased by 18% year-over-year, primarily due to cost containment measures and a workforce reduction. Cash and cash equivalents significantly increased to $53.772 million, bolstered by net proceeds of $48.8 million from a follow-on offering.

Tenaya Therapeutics reported a net loss of $23.8 million for Q4 2024, or $0.28 per share. The company made significant progress in its clinical trials for TN-201 and TN-401, with initial data from MyPEAK-1 Cohort 1 accepted for presentation and dosing initiated in MyPEAK-1 Cohort 2. A recent financing round of $48.9 million extended the cash runway into mid-2026.

Tenaya Therapeutics reported positive safety update and DSMB clearance to dose escalate to Cohort 2 in the MyPEAK-1 study. They remain on track to report early clinical data from the first three patients from Cohort 1 of this study in December. As of September 30, 2024, cash, cash equivalents and investments in marketable securities were $79.5 million.

Tenaya Therapeutics reported its Q2 2024 earnings, highlighting progress in its pipeline programs and strategic collaborations, while facing continued financial challenges typical of a clinical-stage biotechnology company.

Tenaya Therapeutics reported a net loss of $32.2 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $122.2 million, expected to fund operations into the second half of 2025. Clinical trials for TN-201 and TN-401 are ongoing, with initial data from the MyPEAK-1 trial expected in the second half of 2024.

Tenaya Therapeutics reported its Q4 and full year 2023 financial results. The company highlighted the advancement of its genetic medicines portfolio, including progress with TN-201 and TN-401 gene therapy programs. A recent financing is expected to extend the cash runway into the second half of 2025.

Tenaya Therapeutics reported its Q3 2023 financial results, highlighting the commencement of patient dosing in the MyPeak-1 Phase 1b trial of TN-201 and the FDA clearance for TN-401 to begin clinical testing. The company's cash, cash equivalents, and investments are expected to fund operations into the first half of 2025.

Tenaya Therapeutics reported financial results for the second quarter ended June 30, 2023. The company's cash, cash equivalents and investments were $151.6 million as of June 30, 2023, expected to fund operations into the first half of 2025. The company anticipates dosing its first patient in the Phase 1b trial of TN-201 during the third quarter of 2023 and plans to submit an IND application for TN-401 in the second half of 2023.

Tenaya Therapeutics reported its first quarter 2023 financial results, highlighting progress across its business, including Fast Track designation for TN-201 and completion of dosing in the Phase 1 trial of TN-301. The company's cash position remains solid, and it anticipates achieving its 2023 development and regulatory milestones for TN-201, TN-301, and TN-401.

Tenaya Therapeutics reported its Q4 and full year 2022 financial results, highlighting a cash position of $204.2 million and progress in its clinical programs, including the clearance of the TN-201 IND and the commencement of dosing in the TN-301 clinical trial.

Tenaya Therapeutics reported its Q3 2022 financial results, highlighting the extension of its cash runway to mid-2024 and the commencement of dosing in the Phase 1 clinical trial of TN-301. The company ended the quarter with $149.5 million in cash, cash equivalents and investments.

Tenaya Therapeutics reported its Q2 2022 financial results, highlighting progress in becoming a fully integrated clinical-stage company. The company is on track with IND submissions for TN-201 and TN-301 in the second half of 2022 and launched its Genetic Medicines Manufacturing Center.

Tenaya Therapeutics reported its first quarter 2022 financial results, with a net loss of $31.1 million, or $0.75 per share. The company's cash, cash equivalents and investments totaled $213.5 million as of March 31, 2022, expected to fund operations into the second half of 2023. Tenaya continues to advance its pipeline, including TN-201 which received Orphan Medicinal Product designation from the European Commission.

Tenaya Therapeutics reported its Q4 and full year 2021 financial results, highlighting progress in research, preclinical development, manufacturing, and corporate operations. The company is advancing three therapeutic candidates towards clinical trials and strengthening its leadership team.

Tenaya Therapeutics reported its third quarter 2021 financial results, highlighting the initiation of a global natural history study for pediatric patients with MYBPC3 mutations to support clinical development of TN-201 gene therapy, and the initiation of cGMP manufacturing to support the IND filing for TYA-11631 small molecule for HFpEF.

Tenaya Therapeutics reported its Q2 2021 financial results, highlighting a successful IPO that raised $207 million and progress in advancing their gene therapy and precision medicine platforms.